We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

129 hedge funds and large institutions have $340M invested in Karyopharm Therapeutics in 2023 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 52 increasing their positions, 30 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

101% more call options, than puts

Call options by funds: $1.03M | Put options by funds: $515K

73% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 30

2% more capital invested

Capital invested by funds: $334M → $340M (+$5.77M)

0.65% less ownership

Funds ownership: 5.79% → 5.15% (-0.65%)

16% less funds holding

Funds holding: 154 → 129 (-25)

58% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 43

Holders
129
Holders Change
-25
Holders Change %
-16.23%
% of All Funds
2.06%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
18
Increased
52
Reduced
30
Closed
43
Calls
$1.03M
Puts
$515K
Net Calls
+$519K
Net Calls Change
-$184K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$7.59M
2
State Street
State Street
Massachusetts
+$6.22M
3
Barclays
Barclays
United Kingdom
+$5.93M
4
OM
Opaleye Management
Massachusetts
+$5.28M
5
SCM
Silverarc Capital Management
Massachusetts
+$5.07M

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$13.1M
2
RCMNY
Rubric Capital Management (New York)
New York
-$12.7M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$6.77M
4
CC
Commodore Capital
New York
-$6.58M
5
ITP
Iron Triangle Partners
Connecticut
-$6.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
101
Millennium Management
New York
$54K -$1.11M -22,518 -96%
Squarepoint
102
Squarepoint
New York
$48.8K -$131K -2,649 -76%
MC
103
Moors & Cabot
Massachusetts
$47.5K – – –
HSBC Holdings
104
HSBC Holdings
United Kingdom
$46.8K +$40.4K +819 New
BCM
105
Bayesian Capital Management
New York
$46.2K -$105K -2,117 -73%
Victory Capital Management
106
Victory Capital Management
Texas
$45.5K +$38.5K +779 New
Creative Planning
107
Creative Planning
Kansas
$45.1K – – –
AB
108
Amalgamated Bank
New York
$41K -$4.74K -96 -12%
Janney Montgomery Scott
109
Janney Montgomery Scott
Pennsylvania
$39K – – –
Osaic Holdings
110
Osaic Holdings
Arizona
$34.6K – – –
Zurich Cantonal Bank
111
Zurich Cantonal Bank
Switzerland
$32.4K -$12.1K -246 -31%
AIP
112
Ameritas Investment Partners
Nebraska
$24.1K – – –
MLICM
113
Metropolitan Life Insurance Company (MetLife)
New York
$16.6K -$1.14K -23 -7%
Group One Trading
114
Group One Trading
Illinois
$12.1K +$10.2K +207 New
PNC Financial Services Group
115
PNC Financial Services Group
Pennsylvania
$11.7K – – –
FCMT
116
Founders Capital Management (Texas)
Texas
$8K – – –
CUAMC
117
China Universal Asset Management Company
China
$5.97K +$2.32K +47 +85%
MLA
118
MB, Levis & Associates
Pennsylvania
$5.83K – – –
TWC
119
TD Waterhouse Canada
Ontario, Canada
$4.22K – – –
BAM
120
Belpointe Asset Management
Nevada
$3.89K – – –
HI
121
Harbour Investments
Wisconsin
$3.11K – – –
Lazard Asset Management
122
Lazard Asset Management
New York
$3K – – –
Nisa Investment Advisors
123
Nisa Investment Advisors
Missouri
$3K +$197 +4 +8%
AF
124
Advisornet Financial
Minnesota
$2.72K – – –
ASN
125
Advisory Services Network
Georgia
$2.33K – – –
3 4
5
6 7

KPTI Hedge Fund Activity: Q1 2023 in Review

129 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2023, worth a combined $340M — up 1.7% from $334M a quarter earlier.

Sellers outnumbered buyers: 43 funds closed out of KPTI and 18 opened new positions — a net loss of 25 holders — while 30 trimmed existing stakes and 52 added.

The largest buyer was Vanguard Group, adding an estimated $7.59M. The largest seller was Armistice Capital, exiting entirely with an estimated $13.1M sold.

  • 129 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2023, down from 154 in Q4 2022.
  • Funds reported $340M of Karyopharm Therapeutics stock for Q1 2023, up 1.7% quarter-over-quarter.
  • 18 funds opened new Karyopharm Therapeutics positions in Q1 2023 and 43 closed out, a net change of -25 holders.
  • The largest Karyopharm Therapeutics buyer in Q1 2023 was Vanguard Group, an estimated $7.59M added.
  • The largest Karyopharm Therapeutics seller in Q1 2023 was Armistice Capital, an estimated $13.1M sold.

Based on aggregated 13F filings for Q1 2023.